Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 22, 2013 - Issue 8
Submit an article Journal homepage
1,344
Views
21
CrossRef citations to date
0
Altmetric
Drug Evaluations

The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure

Adriaan A VoorsProfessor of Cardiology, University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands+31503612355; +31503614391; [email protected]
, MD PhD,
Bernard DorhoutUniversity of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands
, PhD &
Peter van der MeerUniversity of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands
, MD PhD
Pages 1041-1047 | Published online: 10 May 2013

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Arnold Piek, Weijie Du, Rudolf A. de Boer & Herman H. W. Silljé. (2018) Novel heart failure biomarkers: why do we fail to exploit their potential?. Critical Reviews in Clinical Laboratory Sciences 55:4, pages 246-263.
Read now

Articles from other publishers (20)

Mingxin Zhu, Jianfeng Guo, Badeng Qiqike, Xeri Nay, Shan Dan, Aidina Kuransi, Gaokai Hu, Zhangtong Han, Dong Hou, Ailifeilai Aili, Bin Xia, Ping Chen, Bayin Bate & Jiangjiao Xie. (2023) Sacubitril/Valsartan Cannot Improve Cardiac Function Compared with Valsartan in Patients Suffering Nonvalvular Atrial Fibrillation without Systolic Heart Failure. International Heart Journal 64:6, pages 1032-1039.
Crossref
Xu Jing, Lian Hao, Lin Yuan‐Nan, Liu Wei‐Ke, Jin Lu‐Shen, Ke Jin‐Yan, Chen Yi‐Lian, Qiu Yi‐Xuan, Ge Li‐Sha & Li Yue‐Chun. (2022) The protective effect of LCZ696 in coxsackievirus B3‐induced acute viral myocarditis mice. ESC Heart Failure 10:1, pages 366-376.
Crossref
Ali DUYGU & Emine GAZİ. (2023) Sakubitril valsartan’ın deneysel havyan modellerindeki yeriThe role of sacubitril valsartan in experimental animal models. Troia Medical Journal.
Crossref
Sudhakar Yerra, Kishore Babu Pyata, Sreenivasulu Boju, Hemant Kumar Sharma & Venkateswara Rao Battula. (2022) Development and validation of a novel stability‐indicating reverse phase HPLC method for the determination of sacubitril–valsartan premix stereoisomers: Cellulose tris (4‐methyl benzoate) stationary phase . Journal of Separation Science 45:19, pages 3714-3724.
Crossref
Yue Zhang, Meng Yuan, Ya Suo, Qian Yang, Shuai Shao, Ying Li, Yuanyuan Wang, Qiankun Bao, Tong Liu & Guangping Li. (2022) Angiotensin receptor‐neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction. Clinical and Experimental Pharmacology and Physiology 49:8, pages 848-857.
Crossref
Liu Yang, Min Zhang, Zhiheng Hao, Nan Wang & Min Zhang. (2022) Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients. ESC Heart Failure 9:4, pages 2428-2434.
Crossref
Qi Lou, Lu-yi-fei Li, Guang-zhong Liu, Cheng-chuang Zhan, Li Zhang, Yan-xiang Zang & Wei-min Li. (2022) Effects of Sacubitril/Valsartan on the Expression of CaMKII/Cav1.2 in Atrial Fibrillation Stimulation Rabbit Model. BioMed Research International 2022, pages 1-8.
Crossref
Jerome Roncalli, Hélène Tronchère, Antonio Lax & Oxana Kunduzova. (2022) Editorial: Myocardial Remodeling: Mechanisms and Translational Implications. Frontiers in Pharmacology 13.
Crossref
Jing Liu, Xuehui Zheng, Chen Zhang, Chunmei Zhang & Peili Bu. (2021) Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway. Frontiers in Pharmacology 12.
Crossref
Leonardo Bencivenga, Maria Emiliana Palaia, Immacolata Sepe, Giuseppina Gambino, Klara Komici, Alessandro Cannavo, Grazia Daniela Femminella & Giuseppe Rengo. (2021) Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?. Cells 10:2, pages 457.
Crossref
Lu-yi-fei Li, Qi Lou, Guang-zhong Liu, Jia-chen Lv, Feng-xiang Yun, Tian-kai Li, Wen Yang, Hong-yan Zhao, Li Zhang, Nan Bai, Cheng-chuang Zhan, Jia Yu, Yan-xiang Zang & Wei-min Li. (2020) Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. European Journal of Pharmacology 881, pages 173120.
Crossref
Qing Ge, Li Zhao, Chen Liu, Xiaoming Ren, Yi-hui Yu, Chang Pan & Zuoying Hu. (2020) LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice. BioMed Research International 2020, pages 1-10.
Crossref
Ya Suo, Meng Yuan, Hongmin Li, Yue Zhang, Ying Li, Huaying Fu, Fei Han, Changhui Ma, Yuanyuan Wang, Qiankun Bao & Guangping Li. (2019) Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice. Frontiers in Pharmacology 10.
Crossref
Qing Ge, Li Zhao, Xiao-Min Ren, Peng Ye & Zuo-Ying Hu. (2019) LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis. Experimental Biology and Medicine 244:12, pages 1028-1039.
Crossref
S. Naazneen & A. Sridevi. (2016) DEVELOPMENT OF ASSAY METHOD AND FORCED DEGRADATION STUDY OF VALSARTAN AND SACUBITRIL BY RP-HPLC IN TABLET FORMULATION. International Journal of Applied Pharmaceutics, pages 9-15.
Crossref
Grace Earl & Shelley Hankins. (2016) Angiotensin-receptor-neprilysin inhibition. Nursing Critical Care 11:3, pages 5-8.
Crossref
Yasunori Suematsu, Shin-ichiro Miura, Masaki Goto, Yoshino Matsuo, Tadaaki Arimura, Takashi Kuwano, Satoshi Imaizumi, Atsushi Iwata, Eiji Yahiro & Keijiro Saku. (2016) LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. European Journal of Heart Failure 18:4, pages 386-393.
Crossref
Yoshitsugu Obi, Taehee Kim, Csaba P. Kovesdy, Alpesh N. Amin & Kamyar Kalantar-Zadeh. (2016) Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome. Cardiorenal Medicine 6:2, pages 83-98.
Crossref
Adriaan A. Voors, Mauro Gori, Licette C.Y. Liu, Brian Claggett, Michael R. Zile, Burkert Pieske, John J.V. McMurray, Milton Packer, Victor Shi, Martin P. Lefkowitz & Scott D. Solomon. (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure 17:5, pages 510-517.
Crossref
A. A. Voors & F. Ruschitzka. (2015) The year in cardiology: heart failure 2014. European Heart Journal 36:7, pages 421-424.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.